

# Robert Baughman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9513343/publications.pdf>

Version: 2024-02-01

298  
papers

22,802  
citations

8749

75  
h-index

10441

139  
g-index

312  
all docs

312  
docs citations

312  
times ranked

9841  
citing authors

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 1  | Clinical Characteristics of Patients in a Case Control Study of Sarcoidosis. American Journal of Respiratory and Critical Care Medicine, 2001, 164, 1885-1889.  | 2.5  | 1,455     |
| 2  | An Official American Thoracic Society Clinical Practice Guideline: The Clinical Utility of Bronchoalveolar Lavage Cellular Analysis in Interstitial Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 1004-1014. | 2.5  | 832       |
| 3  | Sarcoidosis. Lancet, The, 2003, 361, 1111-1118.   | 6.3  | 682       |
| 4  | Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. Lancet, The, 1998, 351, 929-933.  | 6.3  | 670       |
| 5  | Infliximab Therapy in Patients with Chronic Sarcoidosis and Pulmonary Involvement. American Journal of Respiratory and Critical Care Medicine, 2006, 174, 795-802.  | 2.5  | 629       |
| 6  | A Case Control Etiologic Study of Sarcoidosis. American Journal of Respiratory and Critical Care Medicine, 2004, 170, 1324-1330.  | 2.5  | 612       |
| 7  | Aerosolized Surfactant in Adults with Sepsis-Induced Acute Respiratory Distress Syndrome. New England Journal of Medicine, 1996, 334, 1417-1422.  | 13.9 | 560       |
| 8  | Pulmonary sarcoidosis. Lancet Respiratory Medicine, the, 2018, 6, 389-402.  | 5.2  | 544       |
| 9  | Utility of a Lung Biopsy for the Diagnosis of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2001, 164, 193-196.  | 2.5  | 525       |
| 10 | Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 2020, 201, e26-e51.  | 2.5  | 521       |
| 11 | A Concise Review of Pulmonary Sarcoidosis. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 573-581.  | 2.5  | 426       |
| 12 | Familial Aggregation of Sarcoidosis. American Journal of Respiratory and Critical Care Medicine, 2001, 164, 2085-2091.  | 2.5  | 422       |
| 13 | Bronchoalveolar Lavage for Diagnosing Acute Bacterial Pneumonia. Journal of Infectious Diseases, 1987, 155, 855-861.  | 1.9  | 306       |
| 14 | The WASOG Sarcoidosis Organ Assessment Instrument: An update of a previous clinical tool. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2014, 31, 19-27.  | 0.2  | 273       |
| 15 | Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. European Respiratory Journal, 2008, 31, 1189-1196.   | 3.1  | 271       |
| 16 | Sarcoidosis in America. Analysis Based on Health Care Use. Annals of the American Thoracic Society, 2016, 13, 1244-1252.  | 1.5  | 257       |
| 17 | ERS clinical practice guidelines on treatment of sarcoidosis. European Respiratory Journal, 2021, 58, 2004079.  | 3.1  | 248       |
| 18 | Definition and Consensus Diagnostic Criteria for Neurosarcoidosis. JAMA Neurology, 2018, 75, 1546.  | 4.5  | 247       |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. ACCESS Research Group. A Case Control Etiologic Study of Sarcoidosis. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 1999, 16, 75-86.   | 0.2 | 231       |
| 20 | Thrombocytopenia in the Intensive Care Unit. Chest, 1993, 104, 1243-1247.   | 0.4 | 215       |
| 21 | Survival in Sarcoidosis-Associated Pulmonary Hypertension. Chest, 2010, 138, 1078-1085.   | 0.4 | 213       |
| 22 | Thalidomide for Chronic Sarcoidosis. Chest, 2002, 122, 227-232.   | 0.4 | 202       |
| 23 | Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2000, 17, 60-6.  | 0.2 | 201       |
| 24 | The Diagnostic Pathway to Sarcoidosis*. Chest, 2003, 123, 406-412.  | 0.4 | 198       |
| 25 | Genetic Variation among Pneumocystis carinii hominis Isolates in Recurrent Pneumocystosis. Journal of Infectious Diseases, 1995, 172, 595-598.  | 1.9 | 191       |
| 26 | Etanercept for Refractory Ocular Sarcoidosis. Chest, 2005, 128, 1062-1067.  | 0.4 | 188       |
| 27 | Six-Minute Walk Test and Health Status Assessment in Sarcoidosis. Chest, 2007, 132, 207-213.  | 0.4 | 178       |
| 28 | Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis. European Respiratory Journal, 2014, 44, 1296-1307.  | 3.1 | 177       |
| 29 | Racial Difference in Sarcoidosis Mortality in the United States. Chest, 2015, 147, 438-449.   | 0.4 | 174       |
| 30 | Treatment of Sarcoidosis. Clinics in Chest Medicine, 2008, 29, 533-548.   | 0.8 | 165       |
| 31 | Infliximab for refractory sarcoidosis. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2001, 18, 70-4.  | 0.2 | 164       |
| 32 | Use of the Protected Specimen Brush in Patients with Endotracheal or Tracheostomy Tubes. Chest, 1987, 91, 233-236.  | 0.4 | 158       |
| 33 | Predictors of Mortality in Pulmonary Sarcoidosis. Chest, 2018, 153, 105-113.  | 0.4 | 152       |
| 34 | The Use of Low Dose Methotrexate in Refractory Sarcoidosis. American Journal of the Medical Sciences, 1990, 299, 153-157.   | 0.4 | 148       |
| 35 | Multinational evidence-based World Association of Sarcoidosis and Other Granulomatous Disorders recommendations for the use of methotrexate in sarcoidosis. Current Opinion in Pulmonary Medicine, 2013, 19, 545-561. | 1.2 | 145       |
| 36 | Bosentan for Sarcoidosis-Associated Pulmonary Hypertension. Chest, 2014, 145, 810-817.  | 0.4 | 144       |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | Presenting characteristics as predictors of duration of treatment in sarcoidosis. QJM - Monthly Journal of the Association of Physicians, 2006, 99, 307-315.   | 0.2 | 139       |
| 38 | Rituximab in the treatment of refractory pulmonary sarcoidosis. European Respiratory Journal, 2014, 43, 1525-1528.   | 3.1 | 133       |
| 39 | Changes in the inflammatory response of the lung during acute respiratory distress syndrome: prognostic indicators.. American Journal of Respiratory and Critical Care Medicine, 1996, 154, 76-81.   | 2.5 | 130       |
| 40 | Decreased Surfactant Protein A in Patients with Bacterial Pneumonia. The American Review of Respiratory Disease, 1993, 147, 653-657.   | 2.9 | 128       |
| 41 | A clinical approach to the use of methotrexate for sarcoidosis. Thorax, 1999, 54, 742-746.   | 2.7 | 124       |
| 42 | Two year prognosis of sarcoidosis: the ACCESS experience. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2003, 20, 204-11.  | 0.2 | 122       |
| 43 | Challenges in Cardiac and Pulmonary Sarcoidosis. Journal of the American College of Cardiology, 2020, 76, 1878-1901.   | 1.2 | 119       |
| 44 | Depression in Sarcoidosis. American Journal of Respiratory and Critical Care Medicine, 2001, 163, 329-334.   | 2.5 | 118       |
| 45 | A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2006, 23, 201-8.               | 0.2 | 118       |
| 46 | Technical Aspects of Bronchoalveolar Lavage: Recommendations for a Standard Procedure. Seminars in Respiratory and Critical Care Medicine, 2007, 28, 475-485.  | 0.8 | 116       |
| 47 | Molecular Genetic Distinction of Pneumocystis carinii from Rats and Humans. Journal of Eukaryotic Microbiology, 1993, 40, 733-741.   | 0.8 | 112       |
| 48 | Health Care Associated Pneumonia (HCAP): A Critical Appraisal to Improve Identification, Management, and Outcomes Proceedings of the HCAP Summit. Clinical Infectious Diseases, 2008, 46, S296-S334. | 2.9 | 111       |
| 49 | Bronchoscopy with Bronchoalveolar Lavage in Tuberculosis and Fungal Infections. Chest, 1991, 99, 92-97.  | 0.4 | 110       |
| 50 | New treatment strategies for pulmonary sarcoidosis: antimetabolites, biological drugs, and other treatment approaches. Lancet Respiratory Medicine, 2015, 3, 813-822.                                | 5.2 | 110       |
| 51 | Established and experimental medical therapy of pulmonary sarcoidosis. European Respiratory Journal, 2013, 41, 1424-1438.  | 3.1 | 109       |
| 52 | Use of bronchoalveolar lavage to diagnose bacterial pneumonia in mechanically ventilated patients. Critical Care Medicine, 1990, 18, 169-173.  | 0.4 | 108       |
| 53 | RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF INFlixIMAB IN PATIENTS WITH CHRONIC PULMONARY SARCOIDOSIS. Chest, 2005, 128, 202S.   | 0.4 | 106       |
| 54 | Genome-wide search for sarcoidosis susceptibility genes in African Americans. Genes and Immunity, 2005, 6, 509-518.  | 2.2 | 106       |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | The Effect of Corticosteroid or Methotrexate Therapy on Lung Lymphocytes and Macrophages in Sarcoidosis. <i>The American Review of Respiratory Disease</i> , 1990, 142, 1268-1271.                              | 2.9 | 105       |
| 56 | Comparison of Gallium-67 Scanning, Bronchoalveolar Lavage, and Serum Angiotensin-Converting Enzyme Levels in Pulmonary Sarcoidosis. <i>The American Review of Respiratory Disease</i> , 1984, 129, 676-681.     | 2.9 | 102       |
| 57 | Release of tumor necrosis factor by alveolar macrophages of patients with sarcoidosis. <i>Translational Research</i> , 1990, 115, 36-42.  | 2.4 | 102       |
| 58 | The continuing utility of bronchoalveolar lavage to diagnose opportunistic infection in AIDS patients. <i>American Journal of Medicine</i> , 1994, 97, 515-522.   | 0.6 | 101       |
| 59 | Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials. <i>Thorax</i> , 2014, 69, 436-444. | 2.7 | 100       |
| 60 | Changes in Chest Roentgenogram of Sarcoidosis Patients During a Clinical Trial of Infliximab Therapy. <i>Chest</i> , 2009, 136, 526-535.  | 0.4 | 98        |
| 61 | Liver-test abnormalities in sarcoidosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2012, 24, 17-24.  | 0.8 | 97        |
| 62 | Infliximab in chronic ocular inflammation. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2005, 43, 7-11.   | 0.3 | 97        |
| 63 | Fatigue in sarcoidosis: a systematic review. <i>Current Opinion in Pulmonary Medicine</i> , 2009, 15, 499-506.  | 1.2 | 96        |
| 64 | Job and Industry Classifications Associated With Sarcoidosis in a Case-â€“Control Etiologic Study of Sarcoidosis (ACCESS). <i>Journal of Occupational and Environmental Medicine</i> , 2005, 47, 226-234.       | 0.9 | 95        |
| 65 | Delphi consensus recommendations for a treatment algorithm in pulmonary sarcoidosis. <i>European Respiratory Review</i> , 2020, 29, 190146.   | 3.0 | 92        |
| 66 | Efficacy and Safety of Apremilast in Chronic Cutaneous Sarcoidosis. <i>Archives of Dermatology</i> , 2012, 148, 262.  | 1.7 | 90        |
| 67 | Defining the clinical outcome status (COS) in sarcoidosis: results of WASOG Task Force. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2011, 28, 56-64.  | 0.2 | 90        |
| 68 | Pulmonary sarcoidosis. <i>Clinics in Chest Medicine</i> , 2004, 25, 521-530.  | 0.8 | 89        |
| 69 | Use of Intermittent, Intravenous Cyclophosphamide for Idiopathic Pulmonary Fibrosis. <i>Chest</i> , 1992, 102, 1090-1094.   | 0.4 | 88        |
| 70 | Double-Blind, Randomized Trial of Dexmethylphenidate Hydrochloride for the Treatment of Sarcoidosis-Associated Fatigue. <i>Chest</i> , 2008, 133, 1189-1195.  | 0.4 | 88        |
| 71 | Cardiac Sarcoidosis. <i>Chest</i> , 2017, 151, 139-148.   | 0.4 | 85        |
| 72 | Ocular Sarcoidosis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2010, 31, 452-462.  | 0.8 | 84        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 73 | Detection of Cryptococcal Antigen in Bronchoalveolar Lavage Fluid: A Prospective Study of Diagnostic Utility. <i>The American Review of Respiratory Disease</i> , 1992, 145, 1226-1229.               | 2.9 | 81        |
| 74 | Evidence-based therapy for cutaneous sarcoidosis. <i>Clinics in Dermatology</i> , 2007, 25, 334-340.  | 0.8 | 80        |
| 75 | Rheumatologic Manifestations of Sarcoidosis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2010, 31, 463-473.   | 0.8 | 80        |
| 76 | STEROID-SPARING ALTERNATIVE TREATMENTS FOR SARCOIDOSIS. <i>Clinics in Chest Medicine</i> , 1997, 18, 853-864.   | 0.8 | 79        |
| 77 | Treatment of Sarcoidosis. <i>Clinical Reviews in Allergy and Immunology</i> , 2015, 49, 79-92.  | 2.9 | 78        |
| 78 | Pulmonary hypertension in sarcoidosis. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2006, 23, 108-16.  | 0.2 | 78        |
| 79 | Inhaled iloprost for sarcoidosis associated pulmonary hypertension. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2009, 26, 110-20.   | 0.2 | 78        |
| 80 | Tumour Necrosis Factor in Sarcoidosis and its Potential for Targeted Therapy. <i>BioDrugs</i> , 2003, 17, 425-431.  | 2.2 | 77        |
| 81 | Clinical characteristics of patients with bone sarcoidosis. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 143-148.  | 1.6 | 76        |
| 82 | Fungal infections as a complication of therapy for sarcoidosis. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2005, 98, 451-456.  | 0.2 | 75        |
| 83 | Repository corticotropin for Chronic Pulmonary Sarcoidosis. <i>Lung</i> , 2017, 195, 313-322.   | 1.4 | 75        |
| 84 | Practical eminence and experience-based recommendations for use of TNF- $\alpha$ inhibitors in sarcoidosis. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2014, 31, 91-107.               | 0.2 | 69        |
| 85 | Calcium and vitamin D metabolism in sarcoidosis. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2013, 30, 113-20.  | 0.2 | 68        |
| 86 | Armodafinil for Sarcoidosis-Associated Fatigue: A Double-Blind, Placebo-Controlled, Crossover Trial. <i>Journal of Pain and Symptom Management</i> , 2013, 45, 159-169.                               | 0.6 | 67        |
| 87 | Management of neurosarcoidosis: a clinical challenge. <i>Current Opinion in Neurology</i> , 2019, 32, 475-483.  | 1.8 | 67        |
| 88 | Physiological predictors of survival in patients with sarcoidosis-associated pulmonary hypertension: results from an international registry. <i>European Respiratory Journal</i> , 2020, 55, 1901747. | 3.1 | 67        |
| 89 | Predicting respiratory failure in sarcoidosis patients. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 1997, 14, 154-8.  | 0.2 | 67        |
| 90 | Management of extrapulmonary sarcoidosis: challenges and solutions. <i>Therapeutics and Clinical Risk Management</i> , 2016, Volume 12, 1623-1634.  | 0.9 | 66        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 91  | Chronic pulmonary aspergillosis complicating sarcoidosis. <i>European Respiratory Journal</i> , 2017, 49, 1602396.   | 3.1 | 66        |
| 92  | Treatment of sarcoidosis: grading the evidence. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 677-687.   | 1.3 | 66        |
| 93  | Therapy for sarcoidosis: evidence-based recommendations. <i>Expert Review of Clinical Immunology</i> , 2012, 8, 95-103.  | 1.3 | 64        |
| 94  | Ocular Manifestations of Sarcoidosis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2002, 23, 543-548.   | 0.8 | 63        |
| 95  | Upper airway.4: Sarcoidosis of the upper respiratory tract (SURT). <i>Thorax</i> , 2010, 65, 181-186.  | 2.7 | 63        |
| 96  | Ventilator-Associated Pneumonia Patients who Do Not Reduce Bacteria from the Lungs have a Worse Prognosis. <i>Journal of Intensive Care Medicine</i> , 2003, 18, 269-274.  | 1.3 | 62        |
| 97  | A retrospective pilot study examining the use of Acthar gel in sarcoidosis patients. <i>Respiratory Medicine</i> , 2016, 110, 66-72.   | 1.3 | 62        |
| 98  | Pulmonary Hypertension in Sarcoidosis. <i>Clinics in Chest Medicine</i> , 2015, 36, 703-714.   | 0.8 | 61        |
| 99  | A Single US Center Experience of Transbronchial Lung Cryobiopsy for Diagnosing Interstitial Lung Disease With a 2-Scope Technique. <i>Journal of Bronchology and Interventional Pulmonology</i> , 2017, 24, 131-135. | 0.8 | 61        |
| 100 | Cardiac Involvement in Sarcoidosis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2002, 23, 513-528.   | 0.8 | 60        |
| 101 | Role of Liver Function Tests in Detecting Methotrexate-Induced Liver Damage in Sarcoidosis. <i>Archives of Internal Medicine</i> , 2003, 163, 615.   | 4.3 | 60        |
| 102 | Nasal and Sinus Manifestations of Sarcoidosis. <i>American Journal of Rhinology &amp; Allergy</i> , 2000, 14, 157-162.   | 2.3 | 58        |
| 103 | Rituximab for refractory granulomatous eye disease. <i>Clinical Ophthalmology</i> , 2012, 6, 1613.   | 0.9 | 58        |
| 104 | Frequency of acute worsening events in fibrotic pulmonary sarcoidosis patients. <i>Respiratory Medicine</i> , 2013, 107, 2009-2013.  | 1.3 | 58        |
| 105 | Nicotine Treatment Improves Toll-Like Receptor 2 and Toll-Like Receptor 9 Responsiveness in Active Pulmonary Sarcoidosis. <i>Chest</i> , 2013, 143, 461-470.   | 0.4 | 58        |
| 106 | Income and Other Contributors to Poor Outcomes in U.S. Patients with Sarcoidosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 955-964.  | 2.5 | 57        |
| 107 | Inhibitors of tumor necrosis factor (TNF) in sarcoidosis: who, what, and how to use them. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2008, 25, 76-89.   | 0.2 | 56        |
| 108 | Clinical features of sarcoidosis associated pulmonary hypertension: Results of a multi-national registry. <i>Respiratory Medicine</i> , 2018, 139, 72-78.  | 1.3 | 55        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 109 | Efficacy Results of a 52-week Trial of Adalimumab in the Treatment of Refractory Sarcoidosis. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2014, 31, 46-54.                             | 0.2 | 55        |
| 110 | Protected-Specimen Brush Technique in the Diagnosis of Ventilator-Associated Pneumonia. Chest, 2000, 117, 203S-206S.   | 0.4 | 54        |
| 111 | The anemia of sarcoidosis. Sarcoidosis, 1988, 5, 51-5.   | 0.4 | 54        |
| 112 | Use of fluticasone in acute symptomatic pulmonary sarcoidosis. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2002, 19, 198-204.  | 0.2 | 54        |
| 113 | Endpoints for clinical trials of sarcoidosis. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2012, 29, 90-8.  | 0.2 | 53        |
| 114 | Utility of bronchoalveolar lavage in assessing pneumonia in immunosuppressed renal transplant recipients. American Journal of Medicine, 1993, 95, 358-364.                                   | 0.6 | 52        |
| 115 | Therapeutic options for sarcoidosis: new and old. Current Opinion in Pulmonary Medicine, 2002, 8, 464-469.   | 1.2 | 52        |
| 116 | Bone Health Issues in Sarcoidosis. Current Rheumatology Reports, 2011, 13, 265-272.  | 2.1 | 52        |
| 117 | Monitoring of Nonsteroidal Immunosuppressive Drugs in Patients With Lung Disease and Lung Transplant Recipients. Chest, 2012, 142, e1S-e111S.  | 0.4 | 52        |
| 118 | Diagnosis and management of neurological sarcoidosis. Archives of Internal Medicine, 1997, 157, 1864-8.  | 4.3 | 52        |
| 119 | Closure Operators and Lattice Extensions. Order, 2004, 21, 43-48.  | 0.3 | 51        |
| 120 | Overexpression of transforming growth factor-alpha and epidermal growth factor-receptor in idiopathic pulmonary fibrosis. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 1999, 16, 57-61. | 0.2 | 51        |
| 121 | Management of ocular sarcoidosis. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2012, 29, 26-33.   | 0.2 | 51        |
| 122 | Predictive value of gallium scan, angiotensin-converting enzyme level, and bronchoalveolar lavage in two-year follow-up of pulmonary sarcoidosis. Lung, 1987, 165, 371-377.                  | 1.4 | 50        |
| 123 | ROLE OF BRONCHOALVEOLAR LAVAGE IN INTERSTITIAL LUNG DISEASE. Clinics in Chest Medicine, 2001, 22, 331-341.   | 0.8 | 50        |
| 124 | The Use of Carbapenems in the Treatment of Serious Infections. Journal of Intensive Care Medicine, 2009, 24, 230-241.  | 1.3 | 48        |
| 125 | Prolonged use of methotrexate for sarcoidosis. Archives of Internal Medicine, 1995, 155, 846-51.   | 4.3 | 48        |
| 126 | Pulmonary and psychosocial findings at enrollment in the ACCESS study. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2005, 22, 147-53.   | 0.2 | 48        |



| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 127 | Increased <i>Pneumocystis carinii</i> Recovery From the Upper Lobes in <i>Pneumocystis</i> Pneumonia. <i>Chest</i> , 1993, 103, 426-432.  | 0.4 | 47        |
| 128 | The Lung in the Immunocompromised Patient. <i>Respiration</i> , 1999, 66, 95-109.   | 1.2 | 46        |
| 129 | Chronic Facial Sarcoidosis Including Lupus Pernio. <i>American Journal of Clinical Dermatology</i> , 2008, 9, 155-161.  | 3.3 | 45        |
| 130 | Pulmonary manifestations of sarcoidosis. <i>Presse Medicale</i> , 2012, 41, e289-e302.  | 0.8 | 45        |
| 131 | Effects of sarcoid and steroids on angiotensin-converting enzyme. <i>The American Review of Respiratory Disease</i> , 1983, 128, 631-3.   | 2.9 | 45        |
| 132 | Inflammatory Profile and Response to Anti-Tumor Necrosis Factor Therapy in Patients with Chronic Pulmonary Sarcoidosis. <i>Vaccine Journal</i> , 2011, 18, 931-939.                     | 3.2 | 44        |
| 133 | Therapeutic approach of hepatic sarcoidosis. <i>Current Opinion in Pulmonary Medicine</i> , 2012, 18, 472-482.  | 1.2 | 44        |
| 134 | Comparison of Sarcoidosis Phenotypes Among Affected African-American Siblings. <i>Chest</i> , 2006, 130, 855-862.   | 0.4 | 43        |
| 135 | Six-minute walk test in managing and monitoring sarcoidosis patients. <i>Current Opinion in Pulmonary Medicine</i> , 2007, 13, 439-444.   | 1.2 | 43        |
| 136 | Refractory Pulmonary Sarcoidosis. <i>Clinical Pulmonary Medicine</i> , 2016, 23, 67-75.   | 0.3 | 43        |
| 137 | High-Risk Sarcoidosis. Current Concepts and Research Imperatives. <i>Annals of the American Thoracic Society</i> , 2017, 14, S437-S444.   | 1.5 | 43        |
| 138 | Changes in fatty acids in phospholipids of the bronchoalveolar fluid in bacterial pneumonia and in adult respiratory distress syndrome.. <i>Clinical Chemistry</i> , 1984, 30, 521-523. | 1.5 | 42        |
| 139 | Pulmonary hypertension associated with sarcoidosis. <i>Arthritis Research and Therapy</i> , 2007, 9, S8.  | 1.6 | 42        |
| 140 | Relapses of sarcoidosis: what are they and can we predict who will get them?. <i>European Respiratory Journal</i> , 2014, 43, 337-339.  | 3.1 | 41        |
| 141 | Sarcoidosis: patient treatment priorities. <i>ERJ Open Research</i> , 2018, 4, 00141-2018.  | 1.1 | 41        |
| 142 | Sarcoidosis Diagnostic Score. <i>Chest</i> , 2018, 154, 1052-1060.  | 0.4 | 41        |
| 143 | Systemic evaluation of a potential cutaneous sarcoidosis patient. <i>Clinics in Dermatology</i> , 2007, 25, 303-311.  | 0.8 | 40        |
| 144 | Safety of performing transbronchial lung cryobiopsy on hospitalized patients with interstitial lung disease. <i>Respiratory Medicine</i> , 2018, 140, 71-76.                            | 1.3 | 40        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 145 | Advanced sarcoidosis. <i>Current Opinion in Pulmonary Medicine</i> , 2019, 25, 497-504.   | 1.2 | 40        |
| 146 | Clinical phenotypes in sarcoidosis. <i>Current Opinion in Pulmonary Medicine</i> , 2014, 20, 496-502.   | 1.2 | 39        |
| 147 | The potential additional benefit of infliximab in patients with chronic pulmonary sarcoidosis already receiving corticosteroids: A retrospective analysis from a randomized clinical trial. <i>Respiratory Medicine</i> , 2014, 108, 189-194. | 1.3 | 39        |
| 148 | Biologic therapies in the treatment of sarcoidosis. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 817-825.  | 1.3 | 38        |
| 149 | Diagnosis and management of spinal cord sarcoidosis. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2006, 23, 58-65.   | 0.2 | 38        |
| 150 | Sarcoidosis: an update on current pharmacotherapy options and future directions. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 2431-2448.  | 0.9 | 37        |
| 151 | Difficult treatment issues in sarcoidosis. <i>Journal of Internal Medicine</i> , 2003, 253, 41-45.  | 2.7 | 36        |
| 152 | Sarcoidosis, role of tumor necrosis factor inhibitors and other biologic agents, past, present, and future concepts. <i>Clinics in Dermatology</i> , 2007, 25, 341-346.   | 0.8 | 36        |
| 153 | When the Game Changes. <i>Chest</i> , 2020, 158, 892-895.   | 0.4 | 36        |
| 154 | Newer Therapies for Cutaneous Sarcoidosis. <i>American Journal of Clinical Dermatology</i> , 2004, 5, 385-394.  | 3.3 | 35        |
| 155 | Who Dies from Sarcoidosis and Why?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 183, 1446-1447.   | 2.5 | 35        |
| 156 | Tadalafil Therapy for Sarcoidosis-Associated Pulmonary Hypertension. <i>Pulmonary Circulation</i> , 2016, 6, 557-562.   | 0.8 | 35        |
| 157 | Effect of obesity on patient-reported outcomes in sarcoidosis. <i>International Journal of Tuberculosis and Lung Disease</i> , 2013, 17, 559-564.   | 0.6 | 34        |
| 158 | The complimentary role of transbronchial lung cryobiopsy and endobronchial ultrasound fine needle aspiration in the diagnosis of sarcoidosis. <i>Respiratory Medicine</i> , 2017, 131, 65-69.   | 1.3 | 33        |
| 159 | Differentiation of sarcoidosis from tuberculosis using real-time PCR assay for the detection and quantification of <i>Mycobacterium tuberculosis</i> . <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2008, 25, 93-9.              | 0.2 | 33        |
| 160 | Sarcoidosis. <i>Chest</i> , 1988, 94, 165-170.  | 0.4 | 32        |
| 161 | It's time to evolve from Scadding: phenotyping sarcoidosis. <i>European Respiratory Journal</i> , 2018, 51, 1800050.  | 3.1 | 32        |
| 162 | Toxicity and Monitoring of Immunosuppressive Therapy Used in Systemic Autoimmune Diseases. <i>Clinics in Chest Medicine</i> , 2010, 31, 565-588.  | 0.8 | 31        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 163 | Medical Therapy of Sarcoidosis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2014, 35, 391-406.  | 0.8 | 30        |
| 164 | Health-Related Quality of Life (HRQoL) in Sarcoidosis: Diagnosis, Management, and Health Outcomes. <i>Diagnostics</i> , 2021, 11, 1089.   | 1.3 | 30        |
| 165 | Fatigue in sarcoidosis: American versus Dutch patients. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2009, 26, 92-7.   | 0.2 | 30        |
| 166 | Is There an Added Value of Cardiopulmonary Exercise Testing in Sarcoidosis Patients?. <i>Lung</i> , 2013, 191, 43-52.   | 1.4 | 29        |
| 167 | Sarcoidosis-Associated Pulmonary Hypertension. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2017, 38, 450-462.   | 0.8 | 29        |
| 168 | Outcome Measures for Clinical Trials in Interstitial Lung Diseases. <i>Current Respiratory Medicine Reviews</i> , 2015, 11, 163-174.  | 0.1 | 29        |
| 169 | Breast disease in sarcoidosis. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2001, 18, 301-6.   | 0.2 | 29        |
| 170 | Use of Bronchoalveolar Lavage Semiquantitative Cultures in Cystic Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1997, 156, 286-291.   | 2.5 | 28        |
| 171 | A Circulating MicroRNA Signature Serves as a Diagnostic and Prognostic Indicator in Sarcoidosis. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2018, 58, 40-54.   | 1.4 | 28        |
| 172 | Endobronchial ultrasound-guided transbronchial needle aspiration in sarcoidosis: Beyond the diagnostic yield. <i>Respirology</i> , 2019, 24, 531-542.   | 1.3 | 28        |
| 173 | WASOG statement on the diagnosis and management of sarcoidosis-associated pulmonary hypertension. <i>European Respiratory Review</i> , 2022, 31, 210165.  | 3.0 | 28        |
| 174 | Right and Left Ventricular Function at Rest and with Exercise in Patients with Sarcoidosis. <i>Chest</i> , 1984, 85, 301-306.   | 0.4 | 27        |
| 175 | Neuro-ophthalmic sarcoidosis. <i>Eye and Brain</i> , 2012, 4, 13.   | 3.8 | 27        |
| 176 | Diagnosis of ventilator-associated pneumonia. <i>Current Opinion in Critical Care</i> , 2003, 9, 397-402.   | 1.6 | 25        |
| 177 | Linkage of Type I Interferon Activity and TNF-Alpha Levels in Serum with Sarcoidosis Manifestations and Ancestry. <i>PLoS ONE</i> , 2011, 6, e29126.  | 1.1 | 25        |
| 178 | Real-time quantitative reverse transcription-polymerase chain reaction to detect propionibacterial ribosomal RNA in the lymph nodes of Chinese patients with sarcoidosis. <i>Clinical and Experimental Immunology</i> , 2015, 181, 511-517. | 1.1 | 25        |
| 179 | Clinical phenotyping: role in treatment decisions in sarcoidosis. <i>European Respiratory Review</i> , 2020, 29, 190145.  | 3.0 | 25        |
| 180 | Tumor necrosis factor inhibition in the treatment of refractory sarcoidosis: slaying the dragon?. <i>Journal of Rheumatology</i> , 2007, 34, 2129-31.   | 1.0 | 25        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 181 | Infliximab for chronic cutaneous sarcoidosis: a subset analysis from a double-blind randomized clinical trial. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2016, 32, 289-95.  | 0.2 | 25        |
| 182 | Current concepts regarding calcium metabolism and bone health in sarcoidosis. <i>Current Opinion in Pulmonary Medicine</i> , 2017, 23, 476-481.   | 1.2 | 24        |
| 183 | Short-Term Particulate Air Pollution Exposure is Associated with Increased Severity of Respiratory and Quality of Life Symptoms in Patients with Fibrotic Sarcoidosis. <i>International Journal of Environmental Research and Public Health</i> , 2018, 15, 1077. | 1.2 | 24        |
| 184 | How the Frequency and Phenotype of Sarcoidosis is Driven by Environmental Determinants. <i>Lung</i> , 2019, 197, 427-436.   | 1.4 | 24        |
| 185 | Riociguat for Sarcoidosis-Associated Pulmonary Hypertension. <i>Chest</i> , 2022, 161, 448-457.   | 0.4 | 24        |
| 186 | The impact of demographic disparities in the presentation of sarcoidosis: A multicenter prospective study. <i>Respiratory Medicine</i> , 2021, 187, 106564.   | 1.3 | 24        |
| 187 | Follow-up Bronchoalveolar Lavage in AIDS Patients with <i>Pneumocystis carinii</i> Pneumonia: <i>Pneumocystis carinii</i> Burden Predicts Early Relapse. <i>The American Review of Respiratory Disease</i> , 1991, 143, 1067-1071.                                | 2.9 | 23        |
| 188 | Ventilator associated pneumonia: quality of nonbronchoscopic bronchoalveolar lavage sample affects diagnostic yield. <i>European Respiratory Journal</i> , 2000, 16, 1152-1157.   | 3.1 | 23        |
| 189 | Phase II Investigation of the Efficacy of Antimycobacterial Therapy in Chronic Pulmonary Sarcoidosis. <i>Chest</i> , 2021, 159, 1902-1912.  | 0.4 | 23        |
| 190 | Novel Therapies for Sarcoidosis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2007, 28, 128-133.   | 0.8 | 21        |
| 191 | The indications for the treatment of sarcoidosis: Wells Law. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2017, 34, 280-282.   | 0.2 | 21        |
| 192 | Management of Advanced Pulmonary Sarcoidosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 495-506.   | 2.5 | 21        |
| 193 | Placenta-derived mesenchymal-like cells (PDA-001) as therapy for chronic pulmonary sarcoidosis: a phase 1 study. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2015, 32, 106-14.  | 0.2 | 21        |
| 194 | Clinical management of pulmonary sarcoidosis. <i>Expert Review of Respiratory Medicine</i> , 2016, 10, 577-591.   | 1.0 | 20        |
| 195 | Advanced Pulmonary Sarcoidosis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2020, 41, 700-715.  | 0.8 | 20        |
| 196 | Semiquantitative technique for estimating <i>Pneumocystis carinii</i> burden in the lung. <i>Journal of Clinical Microbiology</i> , 1990, 28, 1425-1427.  | 1.8 | 20        |
| 197 | Combination therapy for sarcoidosis. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2001, 18, 133-7.   | 0.2 | 20        |
| 198 | Treatment Modalities for Sarcoidosis. <i>Clinical Pulmonary Medicine</i> , 1994, 1, 223-231.  | 0.3 | 19        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 199 | The use of an indirect fluorescent antibody test for detecting <i>Pneumocystis carinii</i> . <i>Archives of Pathology and Laboratory Medicine</i> , 1989, 113, 1062-5.                                 | 1.2 | 19        |
| 200 | Use of a Rapid Differential Stain for Identifying <i>Pneumocystis carinii</i> in Bronchoalveolar Lavage Fluid. <i>Chest</i> , 1989, 95, 494-497.   | 0.4 | 18        |
| 201 | Risk and outcome of COVID-19 infection in sarcoidosis patients: results of a self-reporting questionnaire. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2020, 37, e2020009.               | 0.2 | 18        |
| 202 | Alternatives to corticosteroids in the treatment of sarcoidosis. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 1997, 14, 121-30.   | 0.2 | 18        |
| 203 | Features of sarcoidosis associated with chronic disease. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2015, 31, 275-81.   | 0.2 | 18        |
| 204 | Therapy for Extrapulmonary Sarcoidosis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2002, 23, 589-596.   | 0.8 | 17        |
| 205 | First patient-centred set of outcomes for pulmonary sarcoidosis: a multicentre initiative. <i>BMJ Open Respiratory Research</i> , 2019, 6, e000394.  | 1.2 | 17        |
| 206 | Evaluating the Minimal Clinically Important Difference of the King's Sarcoidosis Questionnaire in a Multicenter Prospective Study. <i>Annals of the American Thoracic Society</i> , 2021, 18, 477-485. | 1.5 | 16        |
| 207 | COVID-19 and Sarcoidosis, Readiness for Vaccination: Challenges and Opportunities. <i>Frontiers in Medicine</i> , 2021, 8, 672028.   | 1.2 | 16        |
| 208 | Prevalence of digital clubbing in bronchogenic carcinoma by a new digital index. <i>Clinical and Experimental Rheumatology</i> , 1998, 16, 21-6.   | 0.4 | 16        |
| 209 | Lobar Pentamidine Levels and <i>Pneumocystis carinii</i> Pneumonia Following Aerosolized Pentamidine. <i>Chest</i> , 1994, 105, 53-56.   | 0.4 | 15        |
| 210 | The six-minute walk test in sarcoidosis associated pulmonary hypertension: Results from an international registry. <i>Respiratory Medicine</i> , 2022, 196, 106801.                                    | 1.3 | 15        |
| 211 | Diagnosis of ventilator-associated pneumonia. <i>Microbes and Infection</i> , 2005, 7, 262-267.  | 1.0 | 14        |
| 212 | Sarcoidosis: is therapy effective?. <i>Seminars in Respiratory Infections</i> , 1998, 13, 255-73.  | 1.3 | 14        |
| 213 | Systemic immune response of patients with active pulmonary sarcoidosis. <i>Clinical and Experimental Immunology</i> , 1985, 61, 535-41.  | 1.1 | 13        |
| 214 | Methotrexate for sarcoidosis. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 1998, 15, 147-9.   | 0.2 | 13        |
| 215 | Diagnostic strategies in <i>Pneumocystis carinii</i> pneumonia. <i>Frontiers in Bioscience - Landmark</i> , 1998, 3, e1-12.  | 3.0 | 12        |
| 216 | Sarcoidosis extent relates to molecular variability. <i>Clinical and Experimental Immunology</i> , 2017, 188, 444-454.   | 1.1 | 12        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 217 | Unsupervised Clustering Reveals Sarcoidosis Phenotypes Marked by a Reduction in Lymphocytes Relate to Increased Inflammatory Activity on 18FDG-PET/CT. <i>Frontiers in Medicine</i> , 2021, 8, 595077. | 1.2 | 12        |
| 218 | Worsening of pulmonary sarcoidosis. <i>Current Opinion in Pulmonary Medicine</i> , 2014, 20, 508-516.  | 1.2 | 11        |
| 219 | Management of repository corticotrophin injection therapy for pulmonary sarcoidosis: a Delphi study. <i>European Respiratory Review</i> , 2020, 29, 190147.  | 3.0 | 11        |
| 220 | Surfactant Replacement for Ventilator-Associated Pneumonia: A Preliminary Report. <i>Respiration</i> , 2002, 69, 57-62.  | 1.2 | 10        |
| 221 | Nonsteroidal therapy for idiopathic pulmonary fibrosis. <i>Current Opinion in Pulmonary Medicine</i> , 2001, 7, 309-313.   | 1.2 | 9         |
| 222 | Executive Summary. <i>Chest</i> , 2012, 142, 1284-1288.  | 0.4 | 9         |
| 223 | Steroids for sarcoidosis: How much and for how long?. <i>Respiratory Medicine</i> , 2018, 138, S5-S6.  | 1.3 | 9         |
| 224 | Assessment of dyspnea in sarcoidosis using the Baseline Dyspnea Index (BDI) and the Transition Dyspnea Index (TDI). <i>Respiratory Medicine</i> , 2022, 191, 106436.                                   | 1.3 | 9         |
| 225 | Repository Corticotropin Injection for the Treatment of Pulmonary Sarcoidosis: A Narrative Review. <i>Pulmonary Therapy</i> , 2022, 8, 43-55.  | 1.1 | 9         |
| 226 | Spontaneous hydrogen peroxide release from alveolar macrophages of patients with active sarcoidosis: comparison with cigarette smokers. <i>Translational Research</i> , 1988, 111, 399-404.            | 2.4 | 9         |
| 227 | Antibiotic resistance in the intensive care unit. <i>Current Opinion in Critical Care</i> , 2002, 8, 430-434.  | 1.6 | 8         |
| 228 | Biologic and advanced immunomodulating therapeutic options for sarcoidosis: a clinical update. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 179-210.                                      | 1.3 | 8         |
| 229 | Infection prevention in sarcoidosis: proposal for vaccination and prophylactic therapy. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2020, 37, 87-98.                                     | 0.2 | 8         |
| 230 | Use of third-line therapies in advanced sarcoidosis. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 834-840.  | 0.4 | 8         |
| 231 | Accuracy of Serial PET-CT Imaging in Systemic Sarcoidosis. <i>Journal of Clinical Imaging Science</i> , 2014, 4, 21.   | 0.4 | 7         |
| 232 | Goldilocks, vitamin D and sarcoidosis. <i>Arthritis Research and Therapy</i> , 2014, 16, 111.  | 1.6 | 7         |
| 233 | Sarcoidosis patient with lupus pernio and infliximab-induced myositis: Response to Acthar gel. <i>Respiratory Medicine Case Reports</i> , 2016, 17, 5-7.   | 0.2 | 7         |
| 234 | Lung derived surface active material (SAM) inhibits natural killer cell tumor cytotoxicity. <i>Journal of Clinical &amp; Laboratory Immunology</i> , 1989, 28, 51-4.                                   | 0.1 | 7         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 235 | Chest high-resolution computed tomography can make higher accurate stages for thoracic sarcoidosis than X-ray. <i>BMC Pulmonary Medicine</i> , 2022, 22, 146.                                     | 0.8 | 7         |
| 236 | The Variability of Sarcoidosis. <i>Chest</i> , 2003, 123, 1329-1332.  | 0.4 | 6         |
| 237 | Methotrexate in sarcoidosis: hematologic and hepatic toxicity encountered in a large cohort over a six year period. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2020, 37, e2020001. | 0.2 | 6         |
| 238 | Can persistent tumor necrosis factor release lead to refractory sarcoidosis?. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2002, 19, 164-6.  | 0.2 | 6         |
| 239 | Microbiologic Diagnosis of Ventilator-Associated Pneumonia. <i>Clinics in Chest Medicine</i> , 2005, 26, 81-86.   | 0.8 | 5         |
| 240 | Sarcoidosis. <i>Clinics in Dermatology</i> , 2007, 25, 231.   | 0.8 | 5         |
| 241 | Clinical trials in pulmonary sarcoidosis. <i>Current Opinion in Pulmonary Medicine</i> , 2015, 21, 525-531.   | 1.2 | 5         |
| 242 | Results of the standard set for pulmonary sarcoidosis: feasibility and multicentre outcomes. <i>ERJ Open Research</i> , 2019, 5, 00094-2019.  | 1.1 | 5         |
| 243 | Current treatment of sarcoidosis. <i>Current Opinion in Pulmonary Medicine</i> , 2020, 26, 591-597.   | 1.2 | 5         |
| 244 | The St. George's Respiratory Questionnaire in Pulmonary Sarcoidosis. <i>Lung</i> , 2020, 198, 917-924.  | 1.4 | 5         |
| 245 | Nonbronchoscopic evaluation of ventilator-associated pneumonia. <i>Seminars in Respiratory Infections</i> , 2003, 18, 95-102.   | 1.3 | 5         |
| 246 | Pneumonia in Immunocompromised and Immunocompetent Patients Requiring Mechanical Ventilation. <i>Journal of Bronchology</i> , 1999, 6, 78-83.   | 0.2 | 4         |
| 247 | Interpretation of the Wright-Giemsa Stained Bronchoalveolar Lavage Specimen. <i>Laboratory Medicine</i> , 2004, 35, 553-557.  | 0.8 | 4         |
| 248 | Considerations in the Choice and Administration of Agents for Empiric Antimicrobial Therapy. <i>Surgical Infections</i> , 2005, 6, s-71-s-82.   | 0.7 | 4         |
| 249 | Sarcoidosis. <i>Clinics in Chest Medicine</i> , 2015, 36, xv.   | 0.8 | 4         |
| 250 | Summary for Clinicians: Clinical Practice Guideline for the Diagnosis and Detection of Sarcoidosis. <i>Annals of the American Thoracic Society</i> , 2020, 17, 1510-1515.                         | 1.5 | 4         |
| 251 | The Value of a Patient Global Assessment in Management of Sarcoidosis. <i>Lung</i> , 2021, 199, 357-362.  | 1.4 | 4         |
| 252 | A composite score to assess treatment response in pulmonary sarcoidosis: the Sarcoidosis Treatment Score (STS). <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2019, 36, 86-88.        | 0.2 | 4         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 253 | An inhibitor of tumor necrosis factor found in pleural effusions. <i>Translational Research</i> , 1991, 118, 326-31.   | 2.4 | 4         |
| 254 | Roflumilast (Daliresp <sup>®</sup> ) to reduce acute pulmonary events in fibrotic sarcoidosis: a multi-center, double blind, placebo controlled, randomized clinical trial. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2021, 38, e2021035.                                    | 0.2 | 4         |
| 255 | Sarcoidosis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2010, 31, 373-374.  | 0.8 | 3         |
| 256 | Treatment of sarcoidosis-associated pulmonary hypertension: so close, and yet so far. <i>European Respiratory Journal</i> , 2017, 50, 1701725.   | 3.1 | 3         |
| 257 | Higher Priced Older Pharmaceuticals. <i>Chest</i> , 2018, 153, 23-33.  | 0.4 | 3         |
| 258 | Sarcoidosis: is cryobiopsy not cool enough? "Authors' reply. <i>Lancet Respiratory Medicine</i> , the, 2018, 6, e45.   | 5.2 | 3         |
| 259 | Symptoms, impacts, and suitability of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT <sup>®</sup> ) questionnaire in patients with sarcoidosis-associated pulmonary hypertension (SAPH): a qualitative interview study. <i>BMC Pulmonary Medicine</i> , 2021, 21, 365. | 0.8 | 3         |
| 260 | Treatment of sarcoidosis. <i>Panminerva Medica</i> , 2013, 55, 175-89.   | 0.2 | 3         |
| 261 | Extrapulmonary Sarcoidosis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2002, 23, 503-504.   | 0.8 | 2         |
| 262 | Diffuse Lung Disease. , 0, , 491-508.  |     | 2         |
| 263 | The Treatment of Pulmonary Sarcoidosis. , 2014, , 41-64.   |     | 2         |
| 264 | Measuring sarcoidosis around the world: Using the same ruler. <i>Revista Portuguesa De Pneumologia</i> , 2017, 23, 247-248.  | 0.7 | 2         |
| 265 | Presence of onconeural antibodies in sarcoidosis patients with parasarcoidosis syndrome. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2019, 36, 254-260.  | 0.2 | 2         |
| 266 | COVID-19 infections in sarcoidosis: a prospective single center study of 886 sarcoidosis patients. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2021, 38, e2021029.   | 0.2 | 2         |
| 267 | The association of baseline sarcoidosis measurements with 6-month outcomes that are of interest to patients: Results from the On-line Sarcoidosis Assessment Platform Study (OSAP). <i>Respiratory Medicine</i> , 2022, 196, 106819.   | 1.3 | 2         |
| 268 | Echocardiographic estimate of pulmonary artery pressure in sarcoidosis patients - real world data from a multi-national study.. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2022, 38, e2021032.  | 0.2 | 2         |
| 269 | New Therapies for Sarcoidosis. <i>Clinical Pulmonary Medicine</i> , 2004, 11, 154-160.   | 0.3 | 1         |
| 270 | Bronchoscopic Evaluation of Moxifloxacin Therapy in Acute Exacerbations of Chronic Bronchitis Previously Treated With Azithromycin. <i>Journal of Bronchology</i> , 2007, 14, 144-148.   | 0.2 | 1         |



| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 271 | 52-Week Trial Results Of Adalimumab As Novel Therapy For Refractory, Progressive Pulmonary Sarcoidosis. , 2010, , .   |     | 1         |
| 272 | TNF- $\alpha$ antagonists and sarcoidosis. QJM - Monthly Journal of the Association of Physicians, 2011, 104, 374-374.  | 0.2 | 1         |
| 273 | Sarcoidosis Mortality. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 462-462.  | 2.5 | 1         |
| 274 | Sarcoidosis-associated fatigue: an often forgotten symptom " author reply. Expert Review of Clinical Immunology, 2013, 9, 111-111.  | 1.3 | 1         |
| 275 | Cardiac sarcoidosis: worse pulmonary function due to left ventricular ejection fraction?. Medicine (United States), 2019, 98, e18037.   | 0.4 | 1         |
| 276 | Mixed Obstructive and Restrictive Ventilatory Defect in Sarcoidosis. Chest, 2020, 158, 1816-1817.   | 0.4 | 1         |
| 277 | Chest CT scan: The best predictor of mortality in advanced pulmonary sarcoidosis?. Respiratory Medicine, 2020, 170, 106059.   | 1.3 | 1         |
| 278 | Advances in predicting patient survival in pulmonary sarcoidosis. Expert Opinion on Orphan Drugs, 2021, 9, 113-122.   | 0.5 | 1         |
| 279 | Diagnosis of Pneumonia in Immunocompromised Patient. , 0, , 53-93.  |     | 1         |
| 280 | Inter-rater reliability of cutaneous sarcoidosis assessment tools via remote photographic assessment. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2017, 34, 165-169.  | 0.2 | 1         |
| 281 | Generalized immune response to Pneumocystis carinii infection in the lung. Journal of Protozoology, 1991, 38, 187S-188S.  | 0.9 | 1         |
| 282 | Isolation of functionally active pleural macrophages. Journal of Clinical & Laboratory Immunology, 1989, 30, 147-51.  | 0.1 | 1         |
| 283 | Sarcoidosis: principles of diagnosis. , 2022, , 57-74.  |     | 1         |
| 284 | Pneumonia in the Immunocompromised Patient. , 2006, , 581-587.  |     | 0         |
| 285 | Infliximab Therapy in Pulmonary Sarcoidosis. American Journal of Respiratory and Critical Care Medicine, 2007, 176, 417a-418.   | 2.5 | 0         |
| 286 | Preface. Clinics in Chest Medicine, 2008, 29, xiii-xiv.   | 0.8 | 0         |
| 287 | Health Effects of Nanoparticles (Inhalation) from Medical Point of View/Type of Diseases. , 2010, , 187-202.  |     | 0         |
| 288 | Is Pulmonary Hypertension Without Left Ventricular Dysfunction Associated With Poor Survival in Patients With Sarcoidosis or Is It Just a Factor of Advanced Disease Stage?: Response. Chest, 2011, 139, 970-971. | 0.4 | 0         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 289 | Complicated Sarcoidosis: Challenges in Dealing with Severe Manifestations. , 2011, , 201-219.   |     | 0         |
| 290 | Sarcoidosis-Associated Pulmonary Hypertension: Diagnosis and Treatment. , 2017, , 129-143.  |     | 0         |
| 291 | Response. Chest, 2018, 153, 1507-1508.  | 0.4 | 0         |
| 292 | Bronchoalveolar Lavage in Interstitial Lung Disease. Lung Biology in Health and Disease, 2003, , 253-272.   | 0.1 | 0         |
| 293 | Drug Therapy for Interstitial Lung Disease. , 2012, , 101-120.  |     | 0         |
| 294 | Sino-Nasal Sarcoidosis. , 2018, , 137-152.  |     | 0         |
| 295 | Considerations in the choice and administration of agents for empiric antimicrobial therapy. Surgical Infections, 2005, 6 Suppl 2, S-71-82.                             | 0.7 | 0         |
| 296 | The lung in autoimmune diseases: sarcoidosis. Handbook of Systemic Autoimmune Diseases, 2022, , 169-188.  | 0.1 | 0         |
| 297 | The calcium-“kidney”-bone axis in sarcoidosis. , 2022, , 193-205.   |     | 0         |
| 298 | World Association for Sarcoidosis and Other Granulomatous Disease (WASOG) Centers of Excellence.. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2022, 38, e2021051. | 0.2 | 0         |